Amgen Inc. Plans Quarterly Dividend of $1.00 (AMGN)
Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Friday, October 14th. Investors of record on Wednesday, November 16th will be paid a dividend of 1.00 per share by the medical research company on Thursday, December 8th. This represents a $4.00 annualized dividend and a yield of 2.47%.
Shares of Amgen (NASDAQ:AMGN) traded down 1.45% during mid-day trading on Friday, reaching $161.90. 2,816,519 shares of the company traded hands. The stock has a market capitalization of $121.16 billion, a PE ratio of 16.57 and a beta of 0.94. Amgen has a 52 week low of $139.02 and a 52 week high of $176.85. The firm has a 50 day moving average of $169.83 and a 200-day moving average of $162.18.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.74 by $0.10. The company earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. Amgen’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.57 earnings per share. On average, equities research analysts expect that Amgen will post $11.35 EPS for the current fiscal year.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.20% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in AMGN. M Holdings Securities Inc. raised its stake in Amgen by 0.3% in the second quarter. M Holdings Securities Inc. now owns 1,725 shares of the medical research company’s stock valued at $262,000 after buying an additional 6 shares in the last quarter. Madison Investment Holdings Inc. raised its stake in Amgen by 4.9% in the second quarter. Madison Investment Holdings Inc. now owns 121,721 shares of the medical research company’s stock valued at $18,520,000 after buying an additional 5,661 shares in the last quarter. Stifel Financial Corp raised its stake in Amgen by 19.1% in the second quarter. Stifel Financial Corp now owns 513,925 shares of the medical research company’s stock valued at $78,194,000 after buying an additional 82,331 shares in the last quarter. Krilogy Financial LLC raised its stake in Amgen by 315.6% in the second quarter. Krilogy Financial LLC now owns 1,496 shares of the medical research company’s stock valued at $228,000 after buying an additional 1,136 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec raised its stake in Amgen by 126.4% in the second quarter. Caisse DE Depot ET Placement DU Quebec now owns 247,803 shares of the medical research company’s stock valued at $37,703,000 after buying an additional 138,353 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.
AMGN has been the subject of several recent analyst reports. BMO Capital Markets reaffirmed a “buy” rating and set a $186.00 price objective on shares of Amgen in a research note on Tuesday, July 12th. Vetr raised shares of Amgen from a “sell” rating to a “hold” rating and set a $165.78 target price for the company in a research note on Wednesday, July 27th. Leerink Swann reissued a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, August 1st. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and set a $206.00 target price (up from $204.00) on shares of Amgen in a research note on Tuesday, September 27th. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. Amgen currently has a consensus rating of “Buy” and a consensus price target of $184.94.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.